These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21827726)

  • 21. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
    Ochała A; Smolka G; Wojakowski W; Gabrylewicz B; Garbocz P; Tendera M
    Kardiol Pol; 2007 Jun; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stents are the CADILLAC of care. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.
    SoRelle R
    Circulation; 2002 Apr; 105(14):e9094-5. PubMed ID: 11942340
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty.
    Fuchs S; Kornowski R; Mehran R; Gruberg L; Satler LF; Pichard AD; Kent KM; Stone GW; Leon MB
    J Invasive Cardiol; 2000 Oct; 12(10):497-501. PubMed ID: 11022207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes.
    Stone GW
    Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577
    [No Abstract]   [Full Text] [Related]  

  • 27. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab to prevent vessel closure after angioplasty.
    Med Lett Drugs Ther; 1995 Jun; 37(950):52-3. PubMed ID: 7760769
    [No Abstract]   [Full Text] [Related]  

  • 29. Platelets and vascular thrombosis.
    Harker LA
    N Engl J Med; 1994 Apr; 330(14):1006-7. PubMed ID: 8121441
    [No Abstract]   [Full Text] [Related]  

  • 30. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
    Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
    Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 33. [MULTISTRATEGY and FATA: merits, limits and troubles of no profit clinical trials in acute myocardial infarction].
    Savonitto S
    G Ital Cardiol (Rome); 2009 Jun; 10(6):364-5. PubMed ID: 19603607
    [No Abstract]   [Full Text] [Related]  

  • 34. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 35. Abciximab in coronary intervention for acute myocardial infarction and stable ischemic heart disease: early investment for growing benefit.
    Ferenczi EA; Malik IS; Mayet J; Foale RA; Francis DP
    J Invasive Cardiol; 2008 Sep; 20(9):437-41. PubMed ID: 18762671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty.
    Lee CW; Moon DH; Hong MK; Lee JH; Choi Si; Yang HS; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2002 Dec; 90(11):1243-6. PubMed ID: 12450607
    [No Abstract]   [Full Text] [Related]  

  • 37. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting?
    Khan JM; Watson RD; Varma C; Millane T; Lip GY
    Int J Clin Pract; 2006 Apr; 60(4):498-9. PubMed ID: 16620368
    [No Abstract]   [Full Text] [Related]  

  • 39. Letter by Lin et al regarding article, "Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention".
    Lin GM; Chu KM; Han CL
    Circulation; 2010 Feb; 121(7):e43; author reply e44-5. PubMed ID: 20177003
    [No Abstract]   [Full Text] [Related]  

  • 40. [Intervention therapy of acute coronary syndrome].
    Yamaguchi T; Nakamura M; Mitsuo K; Matsuda K
    Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1742-8. PubMed ID: 10581757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.